Compare CMPS & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMPS | RLX |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United Kingdom | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 2020 | 2020 |
| Metric | CMPS | RLX |
|---|---|---|
| Price | $14.22 | $1.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | ★ $25.38 | $2.50 |
| AVG Volume (30 Days) | 2.0M | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | ★ 0.75% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.89 |
| Revenue Next Year | N/A | $15.07 |
| P/E Ratio | ★ N/A | $28.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.82 | $1.74 |
| 52 Week High | $15.40 | $2.68 |
| Indicator | CMPS | RLX |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 39.19 |
| Support Level | $13.07 | $1.76 |
| Resistance Level | $14.87 | $2.08 |
| Average True Range (ATR) | 0.65 | 0.05 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 66.30 | 41.67 |
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.